- Home
- NPCT vs CLLS Comparison
NPCT vs CLLS Comparison
Compare NPCT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- CLLS
- Stock Information
- Founded
- NPCT 2020
- CLLS 1999
- Country
- NPCT United States
- CLLS France
- Employees
- NPCT N/A
- CLLS N/A
- Industry
- NPCT Investment Managers
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NPCT Finance
- CLLS Health Care
- Exchange
- NPCT Nasdaq
- CLLS Nasdaq
- Market Cap
- NPCT 314.6M
- CLLS 260.8M
- IPO Year
- NPCT N/A
- CLLS 2007
- Fundamental
- Price
- NPCT $10.96
- CLLS $2.85
- Analyst Decision
- NPCT
- CLLS Buy
- Analyst Count
- NPCT 0
- CLLS 1
- Target Price
- NPCT N/A
- CLLS $4.00
- AVG Volume (30 Days)
- NPCT 107.1K
- CLLS 285.2K
- Earning Date
- NPCT 01-01-0001
- CLLS 08-04-2025
- Dividend Yield
- NPCT 9.82%
- CLLS N/A
- EPS Growth
- NPCT N/A
- CLLS N/A
- EPS
- NPCT N/A
- CLLS N/A
- Revenue
- NPCT N/A
- CLLS $63,438,000.00
- Revenue This Year
- NPCT N/A
- CLLS N/A
- Revenue Next Year
- NPCT N/A
- CLLS $4.90
- P/E Ratio
- NPCT N/A
- CLLS N/A
- Revenue Growth
- NPCT N/A
- CLLS 223.09
- 52 Week Low
- NPCT $8.58
- CLLS $1.10
- 52 Week High
- NPCT $10.63
- CLLS $3.24
- Technical
- Relative Strength Index (RSI)
- NPCT 50.82
- CLLS 62.05
- Support Level
- NPCT $10.88
- CLLS $2.70
- Resistance Level
- NPCT $11.05
- CLLS $2.81
- Average True Range (ATR)
- NPCT 0.10
- CLLS 0.27
- MACD
- NPCT 0.00
- CLLS -0.01
- Stochastic Oscillator
- NPCT 60.06
- CLLS 51.85
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.